We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Interleukin-10 Shown to Reduce Stroke Damage

By HospiMedica staff writers
Posted on 18 Mar 2003
A study has found that stroke patients with higher levels of a natural anti-inflammatory chemical, interleuken-10 (IL-10), in their blood have less brain damage after a stroke. More...
The results were published in the February 21 rapid access issue of Stroke.

In the study, researchers took blood samples from 231 ischemic stroke patients when admitted to a hospital. From the samples, they determined the levels of IL-10 and IL-4. The average time from stroke onset to admission was 8.2 hours. Samples were collected from 80% of patients within 12 hours and from 50% within six hours. Samples were also collected from 43 patients admitted without neurologic disorders, as controls.

The results showed that patients with low levels of IL-10 during the first hours after a stroke were three times more likely to have worsening neurologic symptoms. Specifically, IL-10 concentrations of less than 6 pg/ml were independently associated with clinical worsening within 48 hours. No link was found between stroke progression and IL-4 levels.

"Overall, this study reinforces the growing evidence that anti-inflammatory processes play a major role in human acute ischemia and suggests that IL-10 may have a potential role as a neuroprotectant in acute vascular syndromes,” said co-author Angel Chamorro, M.D., Clinical Institute of Nervous System Diseases (Barcelona, Spain). Dr. Chamorro notes that patients with very low levels of IL-10 may be good candidates for studies of experimental drugs designed to protect brain cells.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.